Moreover, AZA1-treatment also resulted in Rac1 and Cdc42 inhibition associated with suppression of cell proliferation in EGF-stimulated androgen-independent cell lines DU 145 and PC-3 in vitro, supporting the potential of AZA1 for use in prostate cancer. This evidence concerns the gene EGF and prostate carcinoma.